Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2Withdrawn 1Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 84Sarcoma 17Tumor-Agnostic 14CNS 7Genitourinary 5Thoracic 3Gynecologic 3Other solid neoplasm 2Other hematologic neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Solid Tumor 1Advanced Refractory Solid Tumors 1

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × regorafenib × Other solid neoplasm × Clear all
NCT04200404 2022-05-06

A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

CStone Pharmaceuticals

Phase 1/2 Completed
19 enrolled
Other solid neoplasm

Advanced Refractory Solid Tumors

NCT02466802 2020-02-20

Study of Regorafenib and Sildenafil for Advanced Solid Tumors

Virginia Commonwealth University

Phase 1 Completed
32 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡